TRENDS

Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too

By Reiji Anasako June 18, 2019
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…

To read the full story

Related Article

TRENDS

By Reiji Anasako

The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…

By Takashi Ebisawa

Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…

By Takamitsu Sasai

Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…

By Takashi Ebisawa

Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…